IPSEF - Ipsen collaborates with Exicure targeting rare neurodegenerative disorders

Ipsen (OTCPK:IPSEY) and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome. Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome (AS). Exicure will receive a $20M upfront payment and is eligible to receive up to $1B in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties. In the event Ipsen exercises its option, it will be responsible for further development and commercialization of the licensed products. Exicure will be responsible for discovery and certain pre-clinical development activities. HD is a progressive, fatal neurodegenerative disorder characterized by involuntary movements, psychiatric disorders, cognitive deterioration, and early mortality, with death often occurring within 10 to 20 years after motor symptoms appear. AS

For further details see:

Ipsen collaborates with Exicure targeting rare neurodegenerative disorders